Please login to the form below

Not currently logged in
Email:
Password:

Argos Therapeutics

This page shows the latest Argos Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Argos hit as kidney cancer immunotherapy fails phase III trial

Argos hit as kidney cancer immunotherapy fails phase III trial

Argos hit as kidney cancer immunotherapy fails phase III trial. Study discontinued as data shows renal cell carcinoma vaccine unlikely to meet targets. ... Argos Therapeutics' hopes of bringing lead cancer immunotherapy rocapuldencel-T to market anytime

Latest news

  • BMS signs $975m deal for Bavarian Nordic cancer vaccine BMS signs $975m deal for Bavarian Nordic cancer vaccine

    Last year for example, Boehringer Ingelheim licensed rights to CureVac's investigational therapeutic cancer vaccine CV9202 - which it plans to test alongside its Giotrif (afatinib) product - while Argos Therapeutics and Northwest

  • Developing therapeutic cancer vaccines Developing therapeutic cancer vaccines

    AGS 003 consists of dendritic cells that have been loaded with whole tumour RNA using Argos Therapeutics' proprietary Arcelis Personalised Immunotherapy Platform.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics